Amgen Could Get a Piece of the Obesity Market

[ad_1] Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen. [ad_2] Source link

The Big Pharma Stock Trade: Weight Loss Is In, Covid-19 Is Out

[ad_1] What to Read Next [ad_2] Source link

To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit-Card Debts

[ad_1] Some people are paying more than $10,000 a year for Ozempic and Mounjaro. [ad_2] Source link

The Ozempic Craze Could Put These Companies on a Crash Diet

[ad_1] Anti-obesity medications could affect industries that benefit from America’s food problem. [ad_2] Source link

The Obesity Drug Revolution Just Got Real

[ad_1] New data show Novo Nordisk’s Wegovy reduces risk of heart attack and stroke, paving the way for greater insurance coverage. [ad_2] Source link

The Drugs That Are Gaining On Ozempic

[ad_1] If they prove to work safely, the therapies could help people lose so much weight that they supplant bariatric surgery. [ad_2] Source link

Pill for Obesity Has Wall Street Salivating

[ad_1] Obesity treatments are currently limited to injections, but pills could expand the market and lower costs. [ad_2] Source link

No More Shots: Pill Versions of Ozempic-Like Drugs Are Coming

[ad_1] Tablets could appeal to people who want to lose weight but despise needles, which injections like Ozempic require. [ad_2] Source link

Novo Nordisk Invests $2.29 Bln to Expand Manufacturing Facilities in Denmark

[ad_1] Novo Nordisk said it plans to invest $2.3 billion to expand a pharmaceutical ingredient production facility in Denmark for its future portfolio within serious chronic diseases. [ad_2] Source link

Obesity Could Be Pharma’s Biggest Blockbuster Yet

[ad_1] Medications like Wegovy and Mounjaro are about to create one of the biggest drug categories of all time, with massive implications for patients, investors and the healthcare system.The excitement…